Concomitant topiramate resulted in decreased systemic exposure to pioglitazone and its active metabolites , with geometric LSM ratios and @ % CI for AUC@ of @ % ( @ % , @ % ) for pioglitazone , @ % ( @ % , @ % ) for M-III , and @ % ( @ % , @ % ) for M-IV , respectively .